Role of serum and induced sputum surfactant protein D in predicting the response to treatment in chronic obstructive pulmonary disease

Experimental and Therapeutic Medicine

Volumn 8, Issue 4, 2014, Pages 1313-1317

  Liu, Wei ^a,b   Ju, Chun Rong ^a   Chen, Rong Chang ^a   Liu, Zhi Guang ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b HUNAN NORMAL UNIVERSITY   (China)

Author keywords

Biomarker; Chronic obstructive; Pulmonary disease; Surfactant protein D; Treatment response

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; SURFACTANT PROTEIN D;

AGED; ARTICLE; BLOOD ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MODIFIED MEDICAL RESEARCH COUNCIL DYSPNEA SCALE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RATING SCALE; SPUTUM ANALYSIS; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT RESPONSE;

EID: 84906504916     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1865     Document Type: Article

References (32)

1. Vestbo J, Hurd SS, Agustí AG, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187: 347-365, 2013.
2. Wulf-Johansson H, Thinggaard M, Tan Q, et al: Circulating surfactant protein D is associated to mortality in elderly women: a twin study. Immunobiology 218: 712-717, 2013.
3. Sin DD, Man SF, Marciniuk DD, et al; ABC (Advair, Biomarkers in COPD) Investigators: The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177: 1207-1214, 2008.
4. Shakoori TA, Sin DD, Ghafoor F, Bashir S and Bokhari SN: Serum surfactant protein D during acute exacerbations of chronic obstructive pulmonary disease. Dis Markers 27: 287-294, 2009.
5. Ju CR, Liu W and Chen RC: Serum surfactant protein D: biomarker of chronic obstructive pulmonary disease. Dis Markers 32: 281-287, 2012.
6. Sin DD, Leung R, Gan WQ and Man SP: Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med 7: 13, 2007.
7. García-Laorden MI, Rodríguez de Castro F, Solé-Violán J, et al: Influence of genetic variability at the surfactant proteins A and D in community-acquired pneumonia: a prospective, observational, genetic study. Crit Care 15: R57, 2011.
8. Boonarkart CH, Suptawiwat O, Uiprasertkul M, et al: A reduced expression of surfactant protein D in the lungs of fatal influenza H1N1 cases in 2009. Acta Virol 56: 253-255, 2012.
9. Atochina-Vasserman EN, Winkler C, Abramova H, et al: Segmental allergen challenge alters multimeric structure and function of surfactant protein D in humans. Am J Respir Crit Care Med 183: 856-864, 2011.
10. King BA and Kingma PS: Surfactant protein D deficiency increases lung injury during endotoxemia. Am J Respir Cell Mol Biol 44: 709-715, 2011.
11. Ware LB, Koyama T, Billheimer DD, et al; NHLBI ARDS Clinical Trials Network: Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 137: 288-296, 2010.
12. Sin DD, Man SF, McWilliams A and Lam S: Surfactant protein D and bronchial dysplasia in smokers at high risk of lung cancer. Chest 134: 582-588, 2008.
13. Madan T, Reid KB, Clark H, et al: Susceptibility of mice genetically deficient in SP-A or SP-D gene to invasive pulmonary aspergillosis. Mol Immunol 47: 1923-1930, 2010.
14. Ichiyasu H, Ichikado K, Yamashita A, et al: Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in nonspecific interstitial pneumonia. Respiration 83: 190-197, 2012.
15. Lomas DA, Silverman EK, Edwards LD, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigators: Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 34: 95-102, 2009.
16. Vestbo J, Edwards LD, Scanlon PD, et al; ECLIPSE Investigators: Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 365: 1184-1192, 2011.
17. Engström G, Lindberg C, Gerhardsson de Verdier M, et al: Blood biomarkers and measures of pulmonary function-a study from the Swedish twin registry. Respir Med 106: 1250-1257, 2012.
18. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. http://www.goldcopd.org/. Accessed December 31, 2011.
19. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force: Standardisation of spirometry. Eur Respir J 26: 319-338, 2005.
20. Beeh KM, Beier J, Kornmann O and Buhl R: Sputum matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med 97: 634-639, 2003.
21. Sin DD and Vestbo J: Biomarkers in chronic obstructive pulmonary disease. Proc Am Thorac Soc 6: 543-545, 2009.
22. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89-95, 2001.
23. Koutsokera A, Stolz D, Loukides S and Kostikas K: Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge. Chest 141: 396-405, 2012.
24. van Durme YM, Verhamme KM, Aarnoudse AJ, et al: C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. Am J Respir Crit Care Med 179: 375-382, 2009.
25. Hartl D and Griese M: Surfactant protein D in human lung diseases. Eur J Clin Invest 36: 423-435, 2006.
26. Dickens JA, Miller BE, Edwards LD, et al; Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators: COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 12: 146, 2011.
27. Hoegh SV, Sorensen GL, Tornoe I, et al: Long-term stability and circadian variation in circulating levels of surfactant protein D. Immunobiology 215: 314-320, 2010.
28. Wang IM, Stepaniants S, Boie Y, et al: Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med 177: 402-411, 2008.
29. Foreman MG, Kong X, DeMeo DL, et al: Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 44: 316-322, 2011.
30. The Chronic Obstructive Pulmonary Disease group of Chinese Thoracic Society: The diagnosis and treatment guideline of chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi 30: 8-17, 2007 (In Chinese).
31. Braido F, Bagnasco D, Scichilone N, et al: Biomarkers in obstructive respiratory diseases: an update. Panminerva Med 54: 119-127, 2012.
32. Celli BR, Locantore N, Yates J, et al; ECLIPSE Investigators: Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 185: 1065-1072, 2012.